Marinus Pharmaceuticals (MRNS) Downgraded to “Buy” at BidaskClub
BidaskClub cut shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a strong-buy rating to a buy rating in a report released on Tuesday.
Several other equities research analysts have also issued reports on MRNS. ValuEngine lowered shares of Marinus Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, October 6th. Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 8th. Finally, Mizuho reiterated a buy rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of Buy and a consensus price target of $19.67.
Shares of NASDAQ:MRNS opened at $6.28 on Tuesday. Marinus Pharmaceuticals has a 12 month low of $3.31 and a 12 month high of $10.54. The firm has a market cap of $405.25 million, a P/E ratio of -7.86 and a beta of 2.53.
A number of hedge funds have recently modified their holdings of MRNS. BlackRock Inc. increased its stake in Marinus Pharmaceuticals by 316.9% in the 2nd quarter. BlackRock Inc. now owns 2,650,612 shares of the biopharmaceutical company’s stock valued at $18,740,000 after buying an additional 2,014,774 shares during the last quarter. VHCP Management II LLC acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $2,441,000. Northern Trust Corp increased its stake in Marinus Pharmaceuticals by 625.7% in the 2nd quarter. Northern Trust Corp now owns 386,864 shares of the biopharmaceutical company’s stock valued at $2,736,000 after buying an additional 333,555 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Marinus Pharmaceuticals in the 1st quarter valued at $373,000. Finally, Bank of New York Mellon Corp increased its stake in Marinus Pharmaceuticals by 190.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 69,863 shares during the last quarter. Hedge funds and other institutional investors own 63.64% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Featured Story: What is a put option?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.